Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma
Significant clinical benefit beyond current therapies.
The designation marks a major regulatory milestone for Hemispherian, recognizing both the urgent unmet medical need in glioma and the potential of GLIX1 to offer significant clinical benefit beyond current therapies.
"We are proud to have received this recommendation for an Orphan Drug Designation from the EMA Committee. This validates our scientific approach and supports our mission to transform treatment for patients with glioma, who currently face extremely limited and ineffective options," said Zeno Albisser, CEO of Hemispherian.
About the Designation
Following a detailed review, the COMP determined that GLIX1 meets the criteria for orphan designation under Regulation (EC) No 141/2000. In particular:
Glioma is a life-threatening and chronically debilitating disease affecting approximately 2.6 in 10,000 people in the EU.
Existing therapies for Glioblastoma (a form of Glioma) offer only limited survival benefits, with median overall survival typically less than 15 months.
Non-clinical studies with GLIX1 demonstrated significant tumor reduction and extended survival in validated animal models, including cases of complete tumor eradication.
These results suggest that GLIX1 offers a clinically relevant advantage over existing treatments, fulfilling the EMA's criteria for "significant benefit."
Benefits of Orphan Drug Designation- Faster market Access- 10 Years of market Exclusivity
Orphan Drug Designation by the EMA provides Hemispherian with a range of development and commercial incentives, including:
10 years of market exclusivity in the EU upon approval.
Protocol assistance and regulatory guidance from EMA during clinical development.
Eligibility for fee reductions for regulatory submissions, including marketing authorization.
These incentives are designed to encourage the development of innovative treatments for rare diseases with high unmet need.
About Hemispherian
Hemispherian is an Oslo-based pharmaceutical company focused on the development of a novel class of small-molecule drugs targeting glioblastoma and other aggressive cancers. The company's proprietary GLIX platform is based on unique DNA-targeting technology aimed at improving patient survival and quality of life. So far, the treatment shows impressive effects, with limited to no side effects, and with no damage to healthy tissue.
Contact: Zeno Albisser, CEO – zeno@hemispherian.com, +47 40603455
View original content:https://www.prnewswire.com/news-releases/hemispherian-receives-positive-opinion-for-orphan-medicinal-product-designation-in-the-eu-for-glix1-in-glioma-302474492.html
SOURCE Hemispherian AS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen's product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future revenue and profit growth. The acquisition also brought in new growth opportunities, especially with Tepezza, the first FDA-approved treatment for thyroid eye disease. In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported revenue of $8.15 billion, which showed a 9.4% growth from the same period last year. The company reported strong global demand for its products in the first quarter. Management expressed confidence in its long-term growth outlook, citing continued success with new product launches and positive Phase 3 trial results for several treatments. Amgen Inc. (NASDAQ:AMGN)'s free cash flow for the quarter came in at $1.0 billion, up from $0.5 billion in the prior year period. Its operating cash flow was $1.4 billion, compared to $0.7 billion in the same period last year. The company also returned $1.3 billion to shareholders through dividends during the quarter. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.19%, as of July 17. The company has raised its payouts since the inception of its dividend policy in 2011. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Thermo Fisher Scientific (TMO) Announces Strategic Partnership Expansion With Sanofi
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best long term low volatility stocks to buy now. On July 16, Thermo Fisher Scientific Inc. (NYSE:TMO) announced plans to strategically expand its partnership with Sanofi to support additional drug product manufacturing in the United States. A workstation in a research lab stocked with laboratory products and services. As part of the partnership, Thermo Fisher Scientific Inc. (NYSE:TMO) would acquire Sanofi's manufacturing site in Ridgefield, New Jersey, and would continue to produce and develop a portfolio of therapies for Sanofi. Thermo Fisher Scientific Inc. (NYSE:TMO) also plans to expand use of the site to satisfy the rising demand from biotech and pharma customers for US manufacturing capacity. The Ridgefield site will join Thermo Fisher Scientific Inc. (NYSE:TMO) after the completion of the transaction, and comprises a state-of-the-art sterile fill-finish and packaging facility with over 200 employees. Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating
Royalty Pharma plc (NASDAQ:RPRX) is one of the high-margin pharma stocks to buy now. Royalty Pharma plc (NASDAQ:RPRX) received a vote of confidence from Morgan Stanley this week as analyst Terence Flynn raised the firm's price target to $54 from $51 while maintaining an Overweight rating. The adjustment reflects a favorable outlook on the company's cash flow durability and its ability to weather broader industry headwinds. A scientist in a laboratory looking through a microscope, surrounded by petri dishes and beakers while researching new biopharmaceutical advances. Flynn noted in a client note that large-cap pharmaceutical and biotech names have struggled to gain traction this year, weighed down by macroeconomic pressures and lingering regulatory uncertainty. Challenges such as evolving drug pricing frameworks, international tariff exposure, and ongoing personnel shifts within the FDA have all contributed to investor caution across the healthcare space. Despite this backdrop, Royalty Pharma continues to distinguish itself through its unique business model, which centers on acquiring royalty streams tied to established and emerging therapies. The company's portfolio, anchored by revenue from blockbuster drugs such as Tysabri, Imbruvica, and Trelegy, has offered a more stable earnings profile than many of its industry peers. Flynn's upward revision suggests Royalty Pharma remains well-positioned in a sector facing ongoing volatility, with defensive qualities that appeal to investors seeking income and resilience in a complex policy and economic environment. While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
